Loading…
OptimizeRx Corporation operates as a digital healthcare technology company. It offers Dynamic Audience Activation Platform, which generates dynamic audiences with predictive analytics through machine learning methods; Micro-Neighborhood Targeting, which creates consumer audiences using a privacy-first process; Profiler, which provides insights into its customers' target consumers; banner messages, including brand messaging, therapeutic support messaging, affordability messaging, limited distribution drug information, and patient support program messaging through healthcare professionals; and media execution solutions, which deliver messages through consumer omnichannel network, including through programmatic display, programmatic connected television/over-the-top, programmatic social media, addressable television, digital out-of-home, programmatic audio, and email/direct mail. The company also offers pharmacy alerts, which flag pharmacies that have prescription medications in stock; and financial messaging solutions, which provide prescribers visibility to branded copay offers for patients directly within electronic health record systems and ePrescribing platforms. The company was founded in 2006 and is headquartered in Waltham, Massachusetts.
5-year financial trends. Figures in USD millions.
Latest fiscal year: 2025
Year-by-year revenue, profitability, and cash flow (USD millions, last 10 years)
| Year | Revenue | EBITDA | Net Profit | FCF | ROE | Rev Growth 1Y | NP Growth 1Y |
|---|---|---|---|---|---|---|---|
| 2025 | $109M | $17M | $5M | $19M | 4.0% | 18.8% | -125.5% |
| 2024 | $92M | $-9M | $-20M | $4M | -17.2% | 28.8% | 14.5% |
| 2023 | $72M | $-21M | $-18M | $-8M | -13.9% | 14.5% | 53.6% |
| 2022 | $62M | $-9M | $-11M | $10M | -9.1% | - | - |
| 2021 | - | - |
Income statement, balance sheet, and cash flow as reported
Consolidated Figures in USD Millions.
| Metric | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total Revenue | - | 62.45 | 71.52 | 92.13 | 109.43 |
| Operating Revenue | - | 62.45 | 71.52 | 92.13 | 109.43 |
| Cost Of Revenue | - | 23.48 | 28.62 | 32.75 | 35.83 |
| Gross Profit | - | 38.97 | 42.90 | 59.38 | 73.60 |
| Operating Expense | - | 51.26 | 60.42 | 65.60 | 61.53 |
| Selling General And Administration | - | 49.24 | 58.02 | 61.27 | 57.21 |
| Total Expenses | - | 74.74 | 89.04 | 98.34 | 97.37 |
| Operating Income | - | -12.29 | -17.52 | -6.22 | 12.06 |
| Total Operating Income As Reported | - | -12.29 | -26.40 | -13.71 | 11.69 |
| EBITDA | - | -9.42 | -21.31 | -8.90 | 16.57 |
| Normalized EBITDA | - | -9.42 | -12.43 | -1.41 | 16.94 |
| EBIT | - | -11.44 | -23.71 | -13.22 | 12.24 |
| Interest Income | - | 0.85 | 2.19 | 0.33 | 0.35 |
| Interest Expense | - | 0 | 1.45 | 6.16 | 5.29 |
| Net Interest Income | - | 0.85 | 0.74 | -5.83 | -4.94 |
| Other Non Operating Income Expenses | - | - | 0.50 | 0.15 | 0.20 |
| Other Income Expense | - | - | -8.38 | -7.34 | -0.17 |
| Interest Income Non Operating | - | 0.85 | 2.19 | 0.33 | 0.35 |
| Interest Expense Non Operating | - | 0 | 1.45 | 6.16 | 5.29 |
| Net Non Operating Interest Income Expense | - | 0.85 | 0.74 | -5.83 | -4.94 |
| Pretax Income | - | -11.44 | -25.16 | -19.39 | 6.95 |
| Tax Provision | - | 0 | -7.60 | 0.72 | 1.82 |
| Tax Rate For Calcs | - | 0 | 0 | 0 | 0 |
| Tax Effect Of Unusual Items | - | 0 | -2.68 | -1.57 | -0.10 |
| Net Income Continuous Operations | - | -11.44 | -17.57 | -20.11 | 5.13 |
| Net Income From Continuing And Discontinued Operation | - | -11.44 | -17.57 | -20.11 | 5.13 |
| Net Income From Continuing Operation Net Minority Interest | - | -11.44 | -17.57 | -20.11 | 5.13 |
| Net Income | - | -11.44 | -17.57 | -20.11 | 5.13 |
| Net Income Common Stockholders | - | -11.44 | -17.57 | -20.11 | 5.13 |
| Net Income Including Noncontrolling Interests | - | -11.44 | -17.57 | -20.11 | 5.13 |
| Normalized Income | - | -11.44 | -11.37 | -14.19 | 5.40 |
| Diluted NI Availto Com Stockholders | - | -11.44 | -17.57 | -20.11 | 5.13 |
| Basic Average Shares | - | 17.78 | 17.12 | 18.29 | 18.56 |
| Diluted Average Shares | - | 17.78 | 17.12 | 18.29 | 19 |
| Reconciled Depreciation | - | 2.02 | 2.40 | 4.33 | 4.33 |
| Reconciled Cost Of Revenue | - | 23.48 | 28.62 | 32.75 | 35.83 |
| Total Unusual Items | - | 0 | -8.88 | -7.49 | -0.37 |
| Total Unusual Items Excluding Goodwill | - | 0 | -8.88 | -7.49 | -0.37 |
| Special Income Charges | - | 0 | -8.88 | -7.49 | -0.37 |
| Gain On Sale Of Business | - | 0 | -2.14 | 0 | - |
| Impairment Of Capital Assets | - | 0 | 6.74 | 7.49 | 0.37 |
| Restructuring And Mergern Acquisition | 0 | - | - | - | - |
| Depreciation Amortization Depletion Income Statement | - | 2.02 | 2.40 | 4.33 | 4.33 |
| Depreciation And Amortization In Income Statement | - | 2.02 | 2.40 | 4.33 | 4.33 |
| General And Administrative Expense | - | 49.24 | 58.02 | 61.27 | 57.21 |
| Other Gand A | - | 33.49 | 44.30 | 49.80 | 50.24 |
| Salaries And Wages | - | 15.75 | 13.72 | 11.47 | 6.96 |
| Other Operating Expenses | 1.43 | - | - | - | - |
| Selling And Marketing Expense | 1.03 | - | - | - | - |
| Average Dilution Earnings | - | 0 | 0 | 0 | 0 |
Healthcare sector peers, ranked by market cap
| Company | Ticker | Market Cap | P/E | P/B | ROE | EV/EBITDA |
|---|---|---|---|---|---|---|
| OptimizeRx Corporationthis co. | OPRX | $101M | 19.67 | 0.79 | 4.0% | 6.26 |
| The Joint Corp. | JYNT | $117M | 40.32 | 7.80 | 19.3% | 118.19 |
| Aldeyra Therapeutics, Inc. | ALDX | $106M | -3.14 | 2.40 | -76.5% | -1.63 |
| Cardiff Oncology, Inc. | CRDF | $106M | -2.31 | 2.33 | -101.0% | -1.86 |
| Neuronetics, Inc. | STIM | $102M | -2.61 |
| - |
| - |
| - |
| - |
| - |
| 4.54 |
| -174.3% |
| -5.84 |
| Definitive Healthcare Corp. | DH | $96M | -0.69 | 0.34 | -49.4% | -0.74 |
| Heron Therapeutics, Inc. | HRTX | $92M | - | 6.39 | -141.0% | - |
| Outset Medical, Inc. | OM | $88M | -1.07 | 0.69 | -64.3% | -2.46 |
| Aardvark Therapeutics, Inc. | AARD | $86M | -1.49 | 0.81 | -54.0% | -0.63 |
| Peer Median | - | -1.49 | 2.37 | -70.4% | -1.63 | |